Dr. Huertas, a native of Chile, is a physician scientist dedicated to developing therapeutics for inherited metabolic diseases.  He has experience with small molecules, enzyme replacement therapies, and cell and gene therapies. Dr. Huertas has been in the pharmaceutical industry for nearly 30 years in positions of increasing responsibility.  During his professional career, Dr. Huertas has worked with small molecules, biologics and cellular therapies and across multiple therapeutic areas. He led the clinical team that filed for approval of and registered Fabrazyme (agalsidase beta) in the United States, Europe and Japan. In addition, he has extensive experience interacting with regulatory authorities in the US (FDA), EU (EMA), Japan (PMDA) and throughout Latin America. He is very comfortable discussing basic science with scientists, medical science with physicians and investigators, and medical issues with patients, patient associations, physicians, third-party payers and regulators, governmental officials and business colleagues. He has served as an expert advisor to venture capital firms, governmental and non-governmental agencies on issues related to biotechnology and uses of biological resources as means of sustainable economic development.

Dr. Huertas is a graduate of Stanford University (MS, Biochemistry), Harvard University (PhD, Cell and Developmental Biology), the Program in Health Sciences and Technology between Harvard Medical School and the Massachusetts Institute of Technology (MD), and the Sloan School of Management at the Massachusetts Institute of Technology (MS, Management). He trained in Internal Medicine, Rheumatology and Palliative Care at the Massachusetts General Hospital. He is a licensed physician in California and Massachusetts.